Stratton J R, Speck S M, Caldwell J H, Stadius M L, Maynard C, Davis K B, Ritchie J L, Kennedy J W
J Am Coll Cardiol. 1985 May;5(5):1023-8. doi: 10.1016/s0735-1097(85)80001-2.
To determine whether intracoronary streptokinase improves late regional wall motion or reduces left ventricular aneurysm or thrombus formation in patients with acute myocardial infarction, two-dimensional echocardiography was performed at 8 +/- 3 weeks after infarction in 83 patients randomized to streptokinase (n = 45) or standard therapy (n = 38) in the Western Washington Intracoronary Streptokinase Trial. Among the patients treated with streptokinase, the average time to treatment was 4.7 +/- 2.5 hours after the onset of chest pain, and 67% had successful reperfusion. Regional wall motion was assessed in nine left ventricular segments on a scale of 1 to 4 (normal, hypokinetic, akinetic and dyskinetic). Left ventricular thrombus formation was interpreted as positive, equivocal or negative. All patients received anticoagulant therapy in the hospital and 52 received such therapy after hospital discharge. The mean (+/- SD) global (1.5 +/- 0.4 in both groups) and regional wall motion scores in the streptokinase-treated and control groups were not significantly different. The prevalence of aneurysm was 16% in both groups. Left ventricular thrombus was identified in only five patients (positive identification in four, and equivocal in one), all in the streptokinase-treated group (p = NS). There were also no differences between streptokinase and control treatment in any of the echocardiographic variables in subgroups of patients with anterior infarction, inferior infarction, no prior infarction or reperfusion with streptokinase. It is concluded that intracoronary streptokinase given relatively late in the course of acute myocardial infarction does not result in improved global or regional wall motion or a reduction in left ventricular thrombus or aneurysm formation in survivors studied 2 months after myocardial infarction.
为了确定冠状动脉内注射链激酶是否能改善急性心肌梗死患者的晚期局部室壁运动,或减少左心室室壁瘤及血栓形成,在西华盛顿冠状动脉内链激酶试验中,对83例急性心肌梗死患者进行了随机分组,其中45例接受链激酶治疗,38例接受标准治疗。在心肌梗死后8±3周,对这些患者进行了二维超声心动图检查。接受链激酶治疗的患者中,从胸痛发作到治疗的平均时间为4.7±2.5小时,67%的患者实现了再灌注成功。对左心室的9个节段的室壁运动进行1至4级评分(正常、运动减弱、运动消失和运动失调)。左心室血栓形成分为阳性、可疑或阴性。所有患者在住院期间均接受抗凝治疗,52例患者出院后继续接受抗凝治疗。链激酶治疗组和对照组的平均(±标准差)整体室壁运动评分(两组均为1.5±0.4)和局部室壁运动评分无显著差异。两组室壁瘤的发生率均为16%。仅在5例患者中发现左心室血栓(4例确诊,1例可疑),所有这些患者均在链激酶治疗组(p=无显著性差异)。在有前壁梗死、下壁梗死、无前壁梗死或链激酶再灌注的患者亚组中,链激酶治疗与对照治疗在任何超声心动图变量上也没有差异。得出的结论是,在急性心肌梗死病程相对较晚时给予冠状动脉内链激酶,在心肌梗死后2个月对存活患者进行研究时,并不会改善整体或局部室壁运动,也不会减少左心室血栓或室壁瘤的形成。